Longer Antiviral Treatment Prevents Lung Transplant Complications

Jun 15, 2010

(PhysOrg.com) -- Extending the course of treatment to prevent a common virus after lung transplantation dramatically reduces infection rates and possibly the risk of the body rejecting the new lungs, according to research from Duke University Medical Center.

The most prevalent opportunistic infection in lung transplant recipients is cytomegalovirus (CMV), a virus that often has mild effects but can be life threatening for organ transplant recipients. The standard for lung transplant patients is treatment with up to three months of valganciclovir. But even with this therapy, the majority of lung transplant recipients develop CMV infections within a year of their transplant.

The Duke researchers wanted to test the safety and efficacy of extended treatment.

“We found that 12 months of oral valganciclovir (Valcyte, manufactured by Roche) was extremely effective and led to a dramatic reduction in the rate of CMV infection and disease,“ said Scott Palmer, MD, MHS, scientific director of the Lung Transplant Program at Duke. “We also showed that there was no increased or added toxicity with the extended course of treatment.”

“In addition, the study examined viral resistance mutations and demonstrated that extended therapy did not lead to increased , a potential concern with longer courses of treatment,” Palmer added.

Palmer and his colleagues conducted a double-blind, placebo-controlled, randomized study at 11 centers in the United States. They compared the effect of extending the standard three-month therapy for preventing CMV to 12 months. The results are published in the June 15 issue of the .

The study was comprised of 136 participants who completed three months of oral valganciclovir and then 66 received an additional nine months of placebo and 70 received an additional nine months of oral valganciclovir.

was present in 64 percent of the short-course group compared to 10 percent of the extended-course group. CMV disease, or pneumonia caused by CMV virus, occurred in 32 percent of the short-course group and was reduced to 4 percent in the extended-course group.

“Preventing CMV is important because it can directly lead to pneumonia or a viral syndrome, but CMV prevention is even more important because we think CMV is a risk factor for chronic long-term rejection,” Palmer said.

In February, Palmer and his colleagues published research in the American Journal of Respiratory Critical Care Medicine that showed CMV in a patient’s transplanted lungs significantly increases the risk for rejection and leads to worse survival.

“It’s not good enough to say we have drugs to treat CMV, we have to prevent our patients from ever getting CMV,” Palmer said.

Currently, only 50 percent of patients survive five years after transplant, according to Palmer.

“If we want to improve patient outcomes and make them more comparable to other organs, we have to reduce these infections and the complications that come with them,” he said.

Palmer and his team conducted their research based on the idea that there is a critical period after transplant when patients are at high risk of developing CMV.

“It looks like three months is too short, and if we stop the therapy then, the patients will still be at risk. But, maybe 12 months is enough for most patients.”

Palmer and his team also evaluated the patients six months after the treatment ended to ensure they had not just delayed the onset of CMV disease. They found that CMV disease remained extremely low in the 12-18 month window.

“Twelve months of the drug valganciclovir appears to be effective in preventing CMV disease and is not associated with any increased risks or complications. So, I believe most physicians will switch to the extended therapy.”

Explore further: Malaysia quarantines 64 villagers over MERS virus

add to favorites email to friend print save as pdf

Related Stories

It pays to be careful post-kidney transplant

Sep 18, 2009

For kidney transplant recipients, infection with a virus called cytomegalovirus (CMV) may lead to devastating complications. New research suggests that extending the period of preventive treatment after kidney ...

Vaccine against CMV shows promise in clinical trial

Mar 18, 2009

A new vaccine has the potential to be the first to prevent maternal and congenital cytomegalovirus (CMV) infection, according to a University of Alabama at Birmingham (UAB) study published in the March 19 edition of the New En ...

The bowels of infection

Oct 21, 2009

Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," ...

New research explains repeated infection by some viruses

Apr 01, 2010

New research conducted at the Oregon Health & Science University Vaccine and Gene Therapy Institute explains how a virus that has already infected up to 80 percent of the American population can repeatedly re-infect individuals ...

Common virus could cause high blood pressure

May 15, 2009

(PhysOrg.com) -- A new study suggests for the first time that cytomegalovirus (CMV), a common viral infection affecting between 60 and 99 percent of adults worldwide, is a cause of high blood pressure, a leading ...

Recommended for you

Malaysia quarantines 64 villagers over MERS virus

39 minutes ago

Malaysia has quarantined 64 people in a southern village after one of its residents become the country's first person to die of a respiratory illness that is spreading from the Middle East, local media reported Thursday.

Spate of Mideast virus infections raises concerns

1 hour ago

A recent spate of infections from a frequently deadly Middle East virus is raising new worries about efforts to contain the illness, with infectious disease experts urging greater vigilance in combatting ...

New MRSA superbug emerges in Brazil

1 hour ago

An international research team led by Cesar A. Arias, M.D., Ph.D., at The University of Texas Health Science Center at Houston (UTHealth) has identified a new superbug that caused a bloodstream infection ...

User comments : 0

More news stories

Turning off depression in the brain

Scientists have traced vulnerability to depression-like behaviors in mice to out-of-balance electrical activity inside neurons of the brain's reward circuit and experimentally reversed it – but there's ...

Spate of Mideast virus infections raises concerns

A recent spate of infections from a frequently deadly Middle East virus is raising new worries about efforts to contain the illness, with infectious disease experts urging greater vigilance in combatting ...

Clean air: Fewer sources for self-cleaning

Up to now, HONO, also known as nitrous acid, was considered one of the most important sources of hydroxyl radicals (OH), which are regarded as the detergent of the atmosphere, allowing the air to clean itself. ...

Thinnest feasible nano-membrane produced

A new nano-membrane made out of the 'super material' graphene is extremely light and breathable. Not only can this open the door to a new generation of functional waterproof clothing, but also to ultra-rapid filtration. The ...

There's something ancient in the icebox

Glaciers are commonly thought to work like a belt sander. As they move over the land they scrape off everything—vegetation, soil, and even the top layer of bedrock. So scientists were greatly surprised ...